市場調查報告書
商品編碼
1153801
2022-2029 Scopolamine全球市場Global Scopolamine Market - 2022-2029 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
Scopolamine俗稱東莨菪鹼,是一種天然或合成的托烷類生物鹼和抗膽鹼藥。形式上,它用於治療暈車和術後噁心嘔吐。Scopolamine還可以治療胃和腸道問題,例□□如痙攣性肌肉疾病、憩室炎、腸易激綜合徵和帕金森病。
推動全球Scopolamine市場的主要因素不僅是消化系統,還有影響消化系統的飲食習慣和隨意的生活方式。Scopolamine用於治療急性眩暈,增加了眩暈的患病率並促進了市場增長,心理壓力被認為是暈動病的重要因素之一。
由於世界上癌症數量的增加,預計該市場將會增長。
據世界衛生組織統計,2020年死亡人數將達到1000萬,每6人中就有1人死於癌症。其中約 70% 發生在低收入和中等收入國家,最常見的是乳腺癌(2020 年 226 萬例)、肺癌(2020 年約 221 萬例)和結直腸癌(2020 年 193 萬例) ). 案例).因此,化學療法正在興起,導致對Scopolamine製劑的需求。因此,上述因素預計將在預測期內推動市場增長。
預計Scopolamine藥物副作用和產品停產會阻礙市場增長。
然而,Scopolamine的副作用和某些市場參與者的產品停產將阻礙預測期內全球Scopolamine市場的增長。例如,Scopolamine有常見的副作用,如激動、瞳孔散大、放大、視力模糊、意識模糊和眼睛對光的敏感性增加。此外,Perrigo 出於運營原因停止銷售Scopolamine透皮系統,在預測期內減緩了全球Scopolamine市場的增長。
COVID-19 影響分析
由於慢性病導致外科手術數量減少,持續的 COVID-19 大流行對全球Scopolamine市場產生了負面影響。例如,根據國家生物技術信息中心 2020 年 5 月的統計數據,外科手術受到所有危機管理特殊規則的嚴重影響。大流行影響了工作方法、外科手術、微創手術、手術室工作流程、患者和員工安全、培訓、教育等。另一方面,鼓勵外科團隊通過盡可能進行電話和視頻諮詢並停止不必要的隨訪來減少患者的參與。因此,手術次數更少,對麻醉、麻醉鎮痛藥和用於預防術後噁心和嘔吐的Scopolamine透皮貼劑的需求也更少。
The global scopolamine market size was valued around US$ YY million in 2021 and is expected to reach US$ YY million by 2029, growing at a CAGR of YY% during the forecast period (2022-2029).
Scopolamine, commonly known as hyoscine or devil's breath, is a tropane alkaloid and anticholinergic medication that is naturally or synthetically manufactured. It is formally used to treat motion sickness and postoperative nausea and vomiting. Scopolamine may also treat stomach or intestine issues such as spastic muscular states, diverticulitis, irritable bowel syndrome, and Parkinson-like symptoms.
Major factors driving the global scopolamine market are food habits and casual lifestyles, which affect the digestive system as well as the gastrointestinal system; scopolamine is used to treat acute vertigo, increase the prevalence of dizziness, also helps in market growth, and even psychological stress is considered to one of the significant contributor to motion sickness.
According to the WHO statistics, cancer accounted for ten million deaths in the year 2020, about 1 in 6 deaths from cancer. Out of which, around 70% of deaths occurred in low- and middle-income countries; the most common type of cancer are breast (2.26 million cases in 2020), lung (around 2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020). Therefore, it has led to an increase in chemotherapy, which led to the demand for scopolamine drugs. Thus, from the above factors, the market is expected to drive market growth in the forecast period.
However, the side effects of scopolamine and product discontinuation by certain market players hamper the global scopolamine market growth during the forecast period. For instance, scopolamine has common as Agitation, less common side effects such as dilated, bigger, or enlarged pupils (black part of the eye), blurred vision or other changes in vision, confusion, and increased sensitivity of the eyes to light. Furthermore, Perrigo has discontinued the scopolamine transdermal system due to business reasons, thus, slowing the global scopolamine market growth during the forecast.
The ongoing COVID-19 pandemic has negatively impacted the worldwide scopolamine market, owing to a decline in the number of surgical operations resulting from chronic conditions. For instance, according to National Center for Biotechnology Information statistics in May 2020, the surgical practice was greatly impacted by all special rules to manage the crisis. The pandemic impacted working methods, surgical procedures, minimally invasive surgery, theatre workflow, patient and staff safety, training, and education. In contrast, surgical teams were encouraged to offer phone or video consultations wherever possible and cancel non-essential follow-ups to reduce patient interaction. As a result, the number of surgery procedures was reduced, as was the necessity for the scopolamine transdermal patch, which was used to prevent nausea and vomiting following anesthesia, narcotic pain medications, and surgery.
The transdermal patches segment accounted for the largest market share in 2021. The segment benefits because they are preferred for their ease of use, low cost, and availability. The patch is placed behind the ear on the hairless skin and is used to relieve motion sickness caused by anesthetic during surgery. Furthermore, transdermal scopolamine can be eliminated from the body when it is no longer needed. For instance, Novartis AG, Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg is a prescription drug used to treat the symptoms of vomiting caused by motion sickness from anesthesia. Therefore, it has increased the demand for scopolamine transdermal patches. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.
North America region is accounted for the largest market share in 2021. The increasing prevalence of cancer-related surgeries, rising awareness of transdermal scopolamine patches among people, product launches and acquisition and collaborations of market players and FDA approvals in the region are the factors drive the market in the period. For instance, according to the National Cancer Institute, in 2020, 1,806,590 new cases were diagnosed, with 606,520 deaths registered of cancer. In addition, in 2021, around 1.9 million were diagnosed, and 608,570 deaths were confirmed of cancer, as per the American Cancer Society. According to the projection by CDC, new cancer cases per year will rise to 29.5 million by 2040. Besides, cancer-related surgeries have also increased with the increasing demand for scopolamine drugs to treat nausea and vomiting.
Moreover, Ingenus Pharmaceuticals, LLC (Riconpharma LLC.) received approval from the United States Food and Drug Administration in December 2021 to manufacture the generic variant of Transderm-Scop (skin patch). As a result, such advancements tend to boost the region's studied market. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.
Major key players in the scopolamine market are: Baxter International Inc., GlaxoSmithKline plc., Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia and Fine Chemical Corporation.
On March 2, 2022, Athira Pharma, Inc. used scopolamine, a novel small molecule candidate for Parkinson's disease dementia, Alzheimer's, and Dementia with Lewy bodies, and ATH-1020, an orally accessible, brain-penetrant small molecule candidate for neuropsychiatric diseases.
Overview:
Novartis AG is a multinational pharmaceutical company based out of Switzerland. The company engages in developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develop, manufactures, distributes and sells patented pharmaceuticals and comprises two business units: Novartis Oncology and Novartis Pharmaceuticals. Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments. The Sandoz segment develops, manufactures and markets finished dosage form medicines and intermediary products, including active pharmaceutical ingredients.
Product Portfolio:
Transderm Scop (scopolamine) TRANSDERMAL SYSTEM 1.5 mg: Transderm Scop is a prescription medicine used to treat the symptoms of nausea or vomiting caused by motion sickness or from anesthesia.
The global scopolamine report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.
LIST NOT EXHAUSTIVE